Cartalax
Cartalax
Cartalax 40 mg lyophilised reference material for in vitro cartilage and extracellular-matrix research.
| Quantity | Discount | Price each |
|---|---|---|
| 2 | 5% | £37.61 |
| 3 | 7% | £36.82 |
| 4+ | 10% | £35.63 |
Batch reports
Cartalax · 40 mg| Batch | Lab | Result (mg) | Purity (%) | External verification |
|---|---|---|---|---|
| Janoshik | 41.67 mg 41.73 mg 41.22 mg | 99.924% 99.918% 99.923% |
Research Overview
Cartalax 40 mg is supplied as a lyophilised reference material for in vitro laboratory research.
Cartalax is discussed in the context of cartilage and extracellular-matrix research. The precise sequence, molecular weight, purity and batch identity for this stock should be checked against its batch-specific analytical documentation. No clinical effect is claimed.
Store the unopened vial at −20 °C in a dry, desiccated environment and follow the supplier batch documentation and your laboratory SOP.
Technical Specifications
- Lyophilised
- Store −20 °C
- Research use only
No reviews yet. Be the first to review this product.
Naturally occurring copper-binding tripeptide complex investigated for dermal matrix remodelling, wound healing, and tissue regeneration research.
Four-component research blend comprising GHK-Cu, BPC-157, TB-500, and KPV for regenerative pathway and tissue-model studies.
Synthetic α-MSH C-terminal tripeptide reference material for in-vitro peptide-signalling and barrier-model research.
Sold for in vitro laboratory and research purposes. Not a drug, food, cosmetic, dietary supplement, or medical device. Not for human or animal consumption.